Entera Bio Ltd. (ENTX)
ENTXNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$3.25
+0.1100 (+3.50%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $565.25m
- P/E
- –
- EPS, last 4 quarters
- $-0.3900
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.9100 to $4.20
- Average volume
- 472.4k
- Previous close
- $3.14
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $10.00, +207.7% from here
Earnings
Next report
Dec 2025
+22.2%
Mar 2026
+12.5%
Jun 2026
-75.0%
Sep 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.26m | -$3.04m | -$3.54m | -$4.56m |
| Net income | -$3.20m | -$3.02m | -$3.50m | -$7.31m |
News
8 latest- Entera Bio Q3 Loss Widens; Expects Phase 3 Osteoporosis Topline Data In H2'28 RTTNews · 17 hours ago
- Entera Bio Ltd. Reports Third Quarter 2026 Financial Results and $265.9 million Cash BalanceFintel · 3 days ago
- Entera Bio Ltd. Appoints Dr. Juan Camilo Arjona Ferreira to Board of DirectorsFintel · Oct 27, 2026
- Guggenheim Initiates Coverage of Entera Bio with BuyFintel · Sep 25, 2026
- Leerink Partners Initiates Coverage of Entera Bio with Outperform RatingFintel · Sep 18, 2026
- Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA AgreementMarketBeat · Aug 13, 2026
- Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28 RTTNews · Aug 10, 2026
- Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired RTTNews · Jul 27, 2026
The company
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab) and its pipeline of first-in-class oral peptide programs. The Company's most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- enterabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.